Live
FierceBiotechBiopharma moves to reduce development risk earlier than everFierceBiotechIncyte inks $2B deal to add Star unit to late-phase constellation and challenge TakedaEndpoints News#ADA26: Novo Nordisk targets 2030 launch for triple-G obesity shotFierceBiotechWhy Execution Excellence Now Defines Biopharma WinnersFierceBiotechHow integrated strategy is reshaping biopharma growthFierceBiotechBiotech value creation at an inflection pointFierceBiotechGSK pledges £44.5M in near-term for UK biotech to explore cause of liver fibrosis regressionLabiotechTop biotech deals in May 2026PharmaVoice3 potential takeover targets in obesityFierceBiotechHow Unlearn is building a scientific intelligence layer for clinical developmentFierceBiotechHow AI is reshaping biopharma decision-makingFierceBiotechBiopharma IPOs: Timing, capital and staying flexible
BioWorld 23 avr. 2026

Regulatory actions for April 23, 2026

Regulatory actions for April 23, 2026

Original
Contenu indisponible. Consultez la source originale.